Sign In
Buy OMER
$10.16
-0.1000 (-0.97%)
At Close: Jun 03, 2026
Omeros Corporation (OMER) Q4 2022 Earnings Call Transcript
11:17pm, Monday, 13'th Mar 2023
Omeros Corporation (NASDAQ:OMER ) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Dr. Greg Demopulos - Chairman and CEO Mike Jaco
Why Omeros Stock Bolted Higher This Week
02:43pm, Thursday, 09'th Feb 2023
A $200 million milestone payment sparked a rally in the biopharma's shares this week.
Omeros: $200M Added To The Company's Balance Sheet, Upgrading To Strong Buy
08:14am, Wednesday, 08'th Feb 2023
Omeros Corporation's stock has rallied 66% on Feb 6th based on the milestone payment of $200M, which eliminated the potential cash runway overhang some investors were worried about. With the additiona
OMER Stock: Over 50% Surge Explained
12:36pm, Monday, 06'th Feb 2023
The stock price of Omeros Corporation (NASDAQ: OMER) surged by over 50% intraday today. This is why.
Why Omeros Corporation Stock Is Skyrocketing Today
11:30am, Monday, 06'th Feb 2023
The Omeros will now be able to fund operations at least through 2025.
Best Penny Stocks To Buy: 5 To Watch With Big News This Week
10:19am, Monday, 06'th Feb 2023
Penny stocks to watch with big news this week. The post Best Penny Stocks To Buy: 5 To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.co
Omeros: Worst Has Been Priced In, We Like Its IgAN Pipeline, Initiating With A Buy
08:33am, Saturday, 04'th Feb 2023
Omeros corporation's hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) should be considered a free option at this point. Narsoplimab has highly compelling phase 2 data
Omeros' Deafening Silence
01:06am, Tuesday, 27'th Dec 2022
During its Q3 earnings call, Omeros reported on FDA's initial response to its CRL appeal, setting the stage for progress towards approval. Frustratingly, Omeros has not uttered a peep since its Q3 202
Omeros Corporation (OMER) Q3 2022 Earnings Call Transcript
10:34pm, Wednesday, 09'th Nov 2022
Omeros Corporation (NASDAQ:OMER ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive O
Omeros: FDA Appeal On Narsoplimab And Several 2023 Catalysts On Deck
07:08am, Tuesday, 01'st Nov 2022
FDA appeal decision by OND of Narsoplimab for the treatment of patients with HSCT-TMA should be coming in the next few months. Results from the phase 3 ARTEMIS-IGAN study, using Narsoplimab for the tr
Omeros: Taking It To The Max
01:23am, Wednesday, 05'th Oct 2022
Omeros stock has been drifting with a downward bias since it reported its Q4 2021 earnings. Its problem stems from its protracted delay in getting FDA approval of its narsoplimab in treatment of HSCT-
Omeros: Off To Never-Never Land
02:44am, Friday, 19'th Aug 2022
Omeros' lead therapy, narsoplimab in treatment of High-Risk HSCT-TMA, has fumbled repeatedly in front of the FDA. The FDA's latest chapter in this ongoing saga spells progress with a likely high dose
Omeros Corporation (OMER) CEO Gregory Demopulos on Q2 2022 Results - Earnings Call Transcript
08:33pm, Tuesday, 09'th Aug 2022
Omeros Corporation. (NASDAQ:OMER ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Gregory Demopulos - Chairman & Chief Executive
Why Omeros Corporation Stock Is Marching Higher Today
02:48pm, Friday, 29'th Jul 2022
A positive regulatory development is powering the biotech's shares higher today.
Why Omeros Stock Is Freefalling Today
05:46pm, Tuesday, 05'th Jul 2022
It's reverting to where it was before its massive uptick last week.
